1985
DOI: 10.1089/jop.1985.1.137
|View full text |Cite
|
Sign up to set email alerts
|

Mechanism of the Ocular Hypotensive Action of Ketanserin

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
20
0

Year Published

1990
1990
2022
2022

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 31 publications
(20 citation statements)
references
References 10 publications
0
20
0
Order By: Relevance
“…Topical applications of 5-HT 1A agonists have been reported to lower intraocular pressure in rabbits [7,10,26]. Topical application of 5-HT 2A antagonists has been reported to lower intraocular pressure in monkeys [6] and rabbits [19], although the mechanisms of their ocular hypotensive effects remain to be elucidated.…”
Section: Discussionmentioning
confidence: 99%
“…Topical applications of 5-HT 1A agonists have been reported to lower intraocular pressure in rabbits [7,10,26]. Topical application of 5-HT 2A antagonists has been reported to lower intraocular pressure in monkeys [6] and rabbits [19], although the mechanisms of their ocular hypotensive effects remain to be elucidated.…”
Section: Discussionmentioning
confidence: 99%
“…However, it should be noted that although 5-HT 1A receptor agonists altered aqueous dynamics in monkeys, they failed to lower IOP [9], and therefore the situation may not be so straightforward. Table 1 ) The finding that mRNAs encoding subtypes of the 5-HT 2 receptor are expressed by the human ciliary body is of immediate interest to ophthalmologists, since the 5-HT 2 receptor antagonist ketanserin lowers IOP in rabbits, cats and monkeys [2] and in normotensive [8] and ocular hypertensive [7,22] patients. The mechanism of action of ketanserin is thought to involve an increased rate of aqueous outflow, which would be consistent with the presence of 5-HT 2 receptors in the ciliary muscle.…”
Section: Discussionmentioning
confidence: 99%
“…Topical ocular administration of 5-HT 2 receptor antagonists resulted in a decrease in IOP in monkeys (Chang et al, 1985) and humans (Mastropasqua et al, 1997), suggesting utility for such compounds in the treatment of ocular hypertension associated with glaucoma. The 5-HT 2 receptor antagonists ketanserin (Mastropasqua et al, 1997) and sarpogrelate (Takenaka et al, 1995) have been shown to significantly lower IOP in glaucoma patients.…”
mentioning
confidence: 99%